Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX-100 in Advanced Malignancies
NCT03900442Phase 1Completed
- Sponsor
- Prescient Therapeutics
- Start
- Sep 2019
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PTX-100 in peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), angioimmunoblastic T-cell lymphoma (AITL) and 4 more, sponsored by Prescient Therapeutics. Primary endpoints: Rap1 Geranylgeranylation Inhibition at 14 days, Pharmacodynamic Endpoints at 14 days and 4 more. Started Sep 2019; status: completed.
02
Drugs
PTX-100
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)angioimmunoblastic T-cell lymphoma (AITL)multiple myeloma (MM)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03900442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03900442.